<DOC>
	<DOC>NCT01212250</DOC>
	<brief_summary>Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.</brief_summary>
	<brief_title>Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal and Gastric Varices</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients of cirrhosis aged 18 to 75 years who have no esophageal or gastric varices. Any contraindication to betablockers Any past EVL or sclerotherapy Any past history of surgery for portal hypertension Significant cardio or pulmonary comorbidity Any malignancy Refusal to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>